Short term infusion of glycine‐extended gastrin17 stimulates both proliferation and formation of aberrant crypt foci in rat colonic mucosa

Evidence is accumulating that gastrin precursors may act as growth factors for the colonic mucosa in vivo and for colorectal carcinoma cell lines in vitro. The effect of short term administration of synthetic gastrins on the colonic mucosa in vivo, however, has not been reported. The aim of our study was to determine whether continuous systemic infusion of glycine‐extended gastrin17 stimulated proliferation and accelerated carcinogenesis in the colorectal mucosa. A significant increase in colonic mucosal proliferation as assessed by metaphase index was seen in the caecum (23%, p < 0.02) and distal colon (27%, p < 0.001), but not the rectum, after treatment of intact rats with glycine‐extended gastrin17 for 1 week using implanted miniosmotic pumps. Defunctioning of the rectum reduced both the proliferative index and crypt height of the rectal mucosa of untreated rats. Treatment of rectally defunctioned animals with glycine‐extended gastrin17 for either 1 or 4 weeks resulted in a significant increase in both the proliferative index (40% and 93%, respectively) and crypt height (11% and 19%, respectively) of the rectal mucosa. The total number of aberrant crypt foci in intact rats treated with the procarcinogen azoxymethane plus glycine‐extended gastrin17 was increased by 48% compared to the value in controls treated with azoxymethane only (p = 0.01). We conclude that short term administration of glycine‐extended gastrin17 to mature rats not only has a proliferative effect upon colonic mucosa, but also increases the number of aberrant crypt foci formed in the colorectal mucosa after treatment with azoxymethane. Glycine‐extended gastrin17 could thus potentially act as a promoter of carcinogenesis. © 2001 Wiley‐Liss, Inc.

[1]  S. Watson,et al.  Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence , 2000, Gut.

[2]  T. Koh,et al.  Gastrin as a growth factor in the gastrointestinal tract , 2000, Regulatory Peptides.

[3]  T. Wang,et al.  Progastrin expression predisposes mice to colon carcinomas and adenomas in response to a chemical carcinogen. , 2000, Gastroenterology.

[4]  T. Wang,et al.  Mice overexpressing progastrin are predisposed for developing aberrant colonic crypt foci in response to AOM. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[5]  V. Villanacci,et al.  Inhibitory Effect of a Gastrin Receptor Antagonist, CR2945, on 1,2-Dimethylhydrazine-Induced Colorectal Cancer in Mice , 1999, European Surgical Research.

[6]  A. Todisco,et al.  Glycine-extended gastrin regulates HEK cell growth. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[7]  T. Wang,et al.  Overexpression of glycine-extended gastrin in transgenic mice results in increased colonic proliferation. , 1999, The Journal of clinical investigation.

[8]  A. Todisco,et al.  Glycine-Extended Gastrin Exerts Growth-Promoting Effects on Human Colon Cancer Cells , 1999, Molecular medicine.

[9]  W. Creutzfeldt,et al.  Role of Circulating Gastrin in Colorectal Adenomas and Carcinomas , 1999, Digestion.

[10]  B. Evers,et al.  JMV1155: a novel inhibitor of glycine-extended progastrin-mediated growth of a human colon cancer in vivo. , 1999, Anticancer research.

[11]  S. Polak‐Charcon,et al.  Controlled release of TGF‐β1 impedes rat colon carcinogenesis in vivo , 1998, International journal of cancer.

[12]  G. Baldwin,et al.  Gastrin, gastrin receptors and colorectal carcinoma , 1998, Gut.

[13]  G. Baldwin,et al.  Expression of progastrin‐derived peptides and gastrin receptors in a panel of gastrointestinal carcinoma cell lines , 1998, Journal of gastroenterology and hepatology.

[14]  P. Rumsby,et al.  Long-term analysis of colonic aberrant crypt formation after treatment of Sprague-Dawley rats with azoxymethane. , 1998, Teratogenesis, carcinogenesis, and mutagenesis.

[15]  G. Ciccotosto,et al.  Glycine-extended gastrin acts as an autocrine growth factor in a nontransformed colon cell line. , 1997, Gastroenterology.

[16]  H. J. Kim,et al.  Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin. , 1997, Gastroenterology.

[17]  G. Brandi,et al.  Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia , 1997, Gut.

[18]  I. Thorup.  Histomorphological and immunohistochemical characterization of colonic aberrant crypt foci in rats: relationship to growth factor expression. , 1997, Carcinogenesis.

[19]  D. Corpet,et al.  Insulin injections promote the growth of aberrant crypt foci in the colon of rats. , 1997, Nutrition and cancer.

[20]  T. Wang,et al.  Processing and proliferative effects of human progastrin in transgenic mice. , 1996, The Journal of clinical investigation.

[21]  T. Wood,et al.  Gastrin gene expression is required for the proliferation and tumorigenicity of human colon cancer cells. , 1996, Cancer research.

[22]  G. Dockray,et al.  Gastric endocrine cells: gene expression, processing, and targeting of active products. , 1996, Physiological reviews.

[23]  P. O’Brien,et al.  Sulindac and indomethacin inhibit formation of aberrant crypt foci in the colons of dimethyl hydrazine treated rats , 1996, Journal of gastroenterology and hepatology.

[24]  G. Ciccotosto,et al.  Expression, processing, and secretion of gastrin in patients with colorectal carcinoma. , 1995, Gastroenterology.

[25]  W. Chey.  Gut Peptides: Biochemistry and Physiology. , 1995, Gastrointestinal endoscopy.

[26]  S. Pignata,et al.  Hypergastrinemia in rats with azoxymethane‐induced colon cancers , 1995, International journal of cancer.

[27]  B. Kimler,et al.  Drug-induced hypergastrinemia: absence of trophic effects on colonic carcinoma in rats. , 1995, Gastroenterology.

[28]  M. Wargovich,et al.  Inhibition of aberrant crypt growth by non‐steroidal anti‐inflammatory agents and differentiation agents in the rat colon , 1995, International journal of cancer.

[29]  C. Seva,et al.  Growth-promoting effects of glycine-extended progastrin. , 1994, Science.

[30]  P. Singh,et al.  Incomplete processing of progastrin expressed by human colon cancer cells: role of noncarboxyamidated gastrins. , 1994, The American journal of physiology.

[31]  I. Sobhani,et al.  Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. , 1993, Gastroenterology.

[32]  J. Rehfeld,et al.  Expression but incomplete maturation of progastrin in colorectal carcinomas. , 1993, Gastroenterology.

[33]  J. Rehfeld,et al.  Developmental expression of the gastrin and cholecystokinin genes in rat colon. , 1993, Gastroenterology.

[34]  D. Appleton,et al.  Effects of gastrointestinal peptides on azoxymethane-treated colonic mucosa in vitro. , 1991, Carcinogenesis.

[35]  R. Whitehead,et al.  Intravenous but not intracolonic epidermal growth factor maintains colonocyte proliferation in defunctioned rat colorectum. , 1990, Gastroenterology.

[36]  L. Bardram,et al.  Gastrin in non-neoplastic pancreatic tissue from patients with and without gastrinomas. , 1990, Scandinavian journal of gastroenterology.

[37]  L. Bardram,et al.  Progastrin in serum from Zollinger-Ellison patients. An indicator of malignancy? , 1990, Gastroenterology.

[38]  L. Melton,et al.  Risk for colorectal adenocarcinoma in pernicious anemia. A population-based cohort study. , 1989, Annals of internal medicine.

[39]  R. Hoover,et al.  Cancer risk following pernicious anaemia. , 1989, British Journal of Cancer.

[40]  E. Riecken,et al.  Characterization of stereomicroscopically identified preneoplastic lesions during dimethylhydrazine‐induced colonic carcinogenesis , 1988, European journal of clinical investigation.

[41]  R. Bird,et al.  Aberrant crypts: potential preneoplastic lesions in the murine colon. , 1988, Cancer research.

[42]  R. Bird,et al.  Specificity study to evaluate induction of aberrant crypts in murine colons. , 1988, Cancer research.

[43]  R P Bird,et al.  Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. , 1987, Cancer letters.

[44]  N. Wright,et al.  Intravenous but not intragastric urogastrone-EGF is trophic to the intestine of parenterally fed rats , 1984, Regulatory Peptides.

[45]  E. Hamilton.  DIURNAL VARIATION IN PROLIFERATIVE COMPARTMENTS AND THEIR RELATION TO CRYPTOGENIC CELLS IN THE MOUSE COLON , 1979, Cell and tissue kinetics.

[46]  E. Fiala.  Investigations into the metabolism and mode of action of the colon carcinogens 1,2‐dimethylhydrazine and azoxymethane , 1977, Cancer.